Analyst Expectations for Vertex Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) within the last quarter, with a majority leaning towards bullish or somewhat bullish. The average 12-month price target for Vertex Pharmaceuticals, according to 19 analysts, is $368.32, an increase of 5.21% from the previous average price target of $350.08.
August 07, 2023 | 4:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts' ratings and increased price target suggest a positive outlook for Vertex Pharmaceuticals.
The majority of analysts have given bullish or somewhat bullish ratings for Vertex Pharmaceuticals, indicating a positive sentiment towards the stock. Additionally, the increase in the average 12-month price target suggests that analysts expect the stock price to rise in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100